Paper36712949
Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy.
Soriano V and 4 others. Drug Des Devel Ther, 2023. Cited by 23 papers, by iCite.
Cite this record
ConductScience Library. Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy. Papers, record 36712949. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36712949
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antiviral Agents | Major topic |
| Hepatitis B Surface Antigens | Major topic |
| Hepatitis Delta Virus | Major topic |
| Animals | |
| Humans | |
| Drug Discovery | |
| Hepatitis B virus | |
| RNA | |
| Lipopeptides |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT03852433 | Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD) | Background |
Source ClinicalTrials.gov
References51
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27132172 | First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. | J Hepatol | 2016 | https://conductscience.org/library/papers/27132172 | PubMed |
| 2 | 29217749 | Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo. | Gut | 2019 | https://conductscience.org/library/papers/29217749 | PubMed |
| 3 | 35973578 | Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension. | J Hepatol | 2022 | https://conductscience.org/library/papers/35973578 | PubMed |
| 4 | 33999515 | Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life. | Liver Int | 2021 | https://conductscience.org/library/papers/33999515 | PubMed |
| 5 | 23150796 | Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. | Elife | 2012 | https://conductscience.org/library/papers/23150796 | PubMed |
| 6 | 35656722 | T-cell driven allergic cutaneous reaction complicating treatment of hepatitis delta virus infection with bulevirtide. | Liver Int | 2022 | https://conductscience.org/library/papers/35656722 | PubMed |
| 7 | 34699951 | Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis. | J Hepatol | 2022 | https://conductscience.org/library/papers/34699951 | PubMed |
| 8 | 35631038 | Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection. | Pathogens | 2022 | https://conductscience.org/library/papers/35631038 | PubMed |
| 9 | 35942695 | Bulevirtide for patients with compensated chronic hepatitis delta: A review. | Liver Int | 2023 | https://conductscience.org/library/papers/35942695 | PubMed |
| 10 | 31872446 | Spontaneous Clearance of Chronic Delta Hepatitis. | Hepatology | 2020 | https://conductscience.org/library/papers/31872446 | PubMed |
| 11 | 34482769 | Hepatitis D virus (HDV): investigational therapeutic agents in clinical trials. | Expert Opin Investig Drugs | 2022 | https://conductscience.org/library/papers/34482769 | PubMed |
| 12 | 32926353 | Bulevirtide: First Approval. | Drugs | 2020 | https://conductscience.org/library/papers/32926353 | PubMed |
| 13 | 33807170 | In Vivo Models of HDV Infection: Is Humanizing NTCP Enough? | Viruses | 2021 | https://conductscience.org/library/papers/33807170 | PubMed |
| 14 | 32398799 | Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg. | Sci Rep | 2020 | https://conductscience.org/library/papers/32398799 | PubMed |
| 15 | 35934855 | Editorial: pegylated interferon combined with bulevirtide for chronic hepatitis delta-new life for an old timer? Authors' reply. | Aliment Pharmacol Ther | 2022 | https://conductscience.org/library/papers/35934855 | PubMed |
| 16 | 33845061 | Assembly and infection efficacy of hepatitis B virus surface protein exchanges in 8 hepatitis D virus genotype isolates. | J Hepatol | 2021 | https://conductscience.org/library/papers/33845061 | PubMed |
| 17 | 36004554 | Real-life experiences with bulevirtide for the treatment of hepatitis delta-48 weeks data from a German centre. | Liver Int | 2022 | https://conductscience.org/library/papers/36004554 | PubMed |
| 18 | 31292511 | Generation and characterization of a stable cell line persistently replicating and secreting the human hepatitis delta virus. | Sci Rep | 2019 | https://conductscience.org/library/papers/31292511 | PubMed |
| 19 | 35514008 | Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a "real world" study. | Aliment Pharmacol Ther | 2022 | https://conductscience.org/library/papers/35514008 | PubMed |
| 20 | 31541699 | Treatment of chronic hepatitis due to hepatitis B and hepatitis delta virus coinfection. | Int J Antimicrob Agents | 2019 | https://conductscience.org/library/papers/31541699 | PubMed |
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 23 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42713260 | New Developments in the Treatment of Hepatitis B Virus Infection. | Gastroenterol Hepatol (N Y) | 2026 | https://conductscience.org/library/papers/42713260 | PubMed |
| 42630452 | Serum PreS1 antigen combined with vascular endothelial growth factor can identify low-level hepatitis B virus DNA replication in patients with hepatitis B e antigen-negative chronic infection. | Am J Transl Res | 2026 | https://conductscience.org/library/papers/42630452 | PubMed |
| 42486799 | Safety and efficacy of libevitug in patients with chronic hepatitis B and D virus coinfection: A single-center, open-label, phase IIa trial in China. | Hepatol Commun | 2026 | https://conductscience.org/library/papers/42486799 | PubMed |
| 42057812 | Comparative Efficacy of Bulevirtide, Interferons, and Nucleos(t)ide Analogs for Chronic Hepatitis Delta: A Systematic Review and Network Meta-Analysis. | Int J Hepatol | 2026 | https://conductscience.org/library/papers/42057812 | PubMed |
| 41642349 | Insight into the Biology of Hepatitis B Virus and Recent Therapeutic Approaches. | Curr Microbiol | 2026 | https://conductscience.org/library/papers/41642349 | PubMed |
| 40718095 | Harnessing Antiviral Peptides: From Molecular Mechanisms to Clinical Translation. | Curr Res Pharmacol Drug Discov | 2025 | https://conductscience.org/library/papers/40718095 | PubMed |
| 40620504 | Nanoparticle-based therapeutic strategies for chronic liver diseases: Advances and insights. | Liver Res | 2025 | https://conductscience.org/library/papers/40620504 | PubMed |
| 40606936 | Hope on the horizon: Emerging therapies for hepatitis D. | World J Hepatol | 2025 | https://conductscience.org/library/papers/40606936 | PubMed |
| 40038382 | Current prevalence of hepatitis delta diagnosis in Valencia, Spain. | Sci Rep | 2025 | https://conductscience.org/library/papers/40038382 | PubMed |
| 40006617 | Clinical Pharmacology of Bulevirtide: Focus on Known and Potential Drug-Drug Interactions. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/40006617 | PubMed |
| 39100818 | Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide. | JHEP Rep | 2024 | https://conductscience.org/library/papers/39100818 | PubMed |
| 39081834 | Long-Term Treatment with Bulevirtide in Patients with Chronic Hepatitis D and Advanced Chronic Liver Disease. | Can J Gastroenterol Hepatol | 2024 | https://conductscience.org/library/papers/39081834 | PubMed |
| 38977324 | Bile Acid Signaling in Metabolic and Inflammatory Diseases and Drug Development. | Pharmacol Rev | 2024 | https://conductscience.org/library/papers/38977324 | PubMed |
| 38668246 | Prospects for Controlling Hepatitis B Globally. | Pathogens | 2024 | https://conductscience.org/library/papers/38668246 | PubMed |
| 38617106 | The Forgotten Virus, Hepatitis D: A Review of Epidemiology, Diagnosis, and Current Treatment Strategies. | J Clin Exp Hepatol | 2024 | https://conductscience.org/library/papers/38617106 | PubMed |
| 38353882 | Consensus Guidelines: Best Practices for the Prevention, Detection and Management of Hepatitis B Virus Reactivation in Clinical Trials with Immunosuppressive/Immunomodulatory Therapy. | Drug Saf | 2024 | https://conductscience.org/library/papers/38353882 | PubMed |
| 37488783 | Prevalence and determinants of hepatitis delta virus infection among HIV/hepatitis B-coinfected adults in care in the United States. | J Viral Hepat | 2023 | https://conductscience.org/library/papers/37488783 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CXCL10 | 3627 | PubTator's text mining | https://conductscience.org/library/genes/3627 | NCBI Gene |
| ISG15 | 9636 | PubTator's text mining | https://conductscience.org/library/genes/9636 | NCBI Gene |
| SLC10A1 | 6554 | PubTator's text mining | https://conductscience.org/library/genes/6554 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36712949
GET https://conductscience.org/api/papers/v1/36712949/references?page=2